| Overview |
| v5801-1mg |
| Human UCHL1/PGP9.5 Mouse Monoclonal Antibody |
| ELISA, LFA |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Monoclonal |
| 1.10E+05 |
| IgG2a |
| Lot Dependent |
| affinity purified by Protein A |
| 0.01M PBS(pH7.4). |
| Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 7345 |
| Gracile axonal dystrophy; Neuron cytoplasmic protein 9.5; Park 5; Park5; Parkinson Disease 5; PGP 9.5; PGP95; Protein gene product 9.5; Ubiquitin C terminal esterase L1; Ubiquitin C terminal hydrolase (neuron specific); Ubiquitin C terminal hydrolase; Ubiquitin carboxyl terminal esterase L1; Ubiquitin carboxyl terminal hydrolase isozyme L1; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin thioesterase L1; Ubiquitin thiolesterase; Ubiquitin thiolesterase L1; UCH-L1; UCHL1; UCHL1_HUMAN. |
| catalyzes the hydrolysis of ubiquitin carboxy-terminal thiolesters to form ubiquitin and a thiol; may play a role in neuropathic pain [RGD].
Found in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and Alzheimer disease patients. |
| Application Dilution |
| ELISA |
1:500-1000 |
| LFA |
N/A |